Pflug Koory LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,290 shares of the medical research company’s stock after selling 254 shares during the quarter. Thermo Fisher Scientific makes up 1.8% of Pflug Koory LLC’s portfolio, making the stock its 6th largest holding. Pflug Koory LLC’s holdings in Thermo Fisher Scientific were worth $2,269,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of TMO. Oregon Public Employees Retirement Fund raised its stake in Thermo Fisher Scientific by 44,296.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 19,565,960 shares of the medical research company’s stock worth $87,000 after acquiring an additional 19,521,889 shares in the last quarter. Norges Bank acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $946,280,000. FMR LLC raised its stake in Thermo Fisher Scientific by 33.4% during the fourth quarter. FMR LLC now owns 8,671,713 shares of the medical research company’s stock worth $1,940,642,000 after acquiring an additional 2,172,574 shares in the last quarter. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 3.7% during the fourth quarter. BlackRock Inc. now owns 26,177,278 shares of the medical research company’s stock worth $5,858,214,000 after acquiring an additional 944,035 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Thermo Fisher Scientific by 71.4% during the third quarter. AQR Capital Management LLC now owns 1,499,423 shares of the medical research company’s stock worth $365,979,000 after acquiring an additional 624,602 shares in the last quarter. 88.66% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:TMO opened at $280.65 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $202.83 and a twelve month high of $282.98. The firm has a market capitalization of $111.92 billion, a PE ratio of 25.24, a price-to-earnings-growth ratio of 1.85 and a beta of 1.13. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.73 and a quick ratio of 1.24.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. During the same period last year, the company posted $2.79 earnings per share. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.15 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 16th. Investors of record on Friday, March 15th will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.
Several research analysts have issued reports on TMO shares. BTIG Research increased their price objective on Thermo Fisher Scientific to $290.00 and gave the stock a “buy” rating in a research note on Thursday, January 31st. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 price objective for the company in a research note on Tuesday, April 9th. UBS Group increased their price objective on Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. Deutsche Bank raised their target price on Thermo Fisher Scientific from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. Finally, Robert W. Baird raised their target price on Thermo Fisher Scientific from $270.00 to $288.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $289.00.
In related news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $266.00, for a total value of $665,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gregory J. Herrema sold 3,299 shares of Thermo Fisher Scientific stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $263.05, for a total value of $867,801.95. The disclosure for this sale can be found here. Over the last quarter, insiders sold 36,927 shares of company stock valued at $9,388,124. Corporate insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: Swap
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.